Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations

    January 2024 in “ Curēus
    Philip A Holubeck, Andrew C Eksi, K Gillett, James O’Hara, Daniel J McGoldrick, D. Clayton Brown, Alec McCarthy
    Image
    Studysummary This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results